NasdaqCM:SLNOBiotechs
Soleno Therapeutics (SLNO) Is Down 9.8% After Report Raises Doubts on VYKAT XR Trial Integrity
Earlier this month, Soleno Therapeutics came under scrutiny after a critical Scorpion Capital report raised concerns about the safety of its drug VYKAT™ XR and questioned clinical trial data integrity.
The resulting investigations by multiple law firms have amplified doubts over the company's regulatory and commercial pathway for its lead therapy.
We'll take a closer look at how questions about VYKAT™ XR's trial data are shaping the investment narrative for Soleno Therapeutics.
The end of...